Person: KIRPINAR, İSMET
10 results
Search Results
Now showing 1 - 10 of 10
Publication Open Access COVID-19 infection, vaccine status, and avoidance behaviors in adults with attention deficit and hyperactivity disorder: A cross-sectional study(2022-08-01) KILIÇ Ö.; BOYLU M. E.; Karakaya-Erdur S.; Suma-Berberoglu M.; Gudjonsson G.; Young S.; Deveci E.; KIRPINAR İ.; KILIÇ, ÖZGE; BOYLU, MUHAMMED EMİN; DEVECİ, ERDEM; KIRPINAR, İSMETObjective: We aim to examine infection risk and vaccine status of COVID-19 in attention deficit and hyperactivity disorder and evaluate the impact of demographic, clinical, and COVID-19-related factors on the infection status and behavioral avoidance of COVID-19. Methods: This cross-sectional study assessed adults with attention deficit and hyperactivity disorder recruited from an outpatient psychiatry clinic. Patients and healthy controls completed a survey on sociodemographic data, COVID-19 infection status, and vaccine status. COVID-19 Disease Perception Scale, COVID-19 Avoidance Attitudes Scale, Attitudes toward COVID-19 Vaccine Scale, Adult Attention Deficit and Hyperactivity Disorder Self-report Screening Scale for DSM-5, Adult Attention Deficit and Hyperactivity Disorder Self-Report Scale Symptoms Checklist, Patient Health Questionnaire-9, and State-Trait Anxiety Inventory were applied. Results: Ninety patients and 40 healthy controls participated. Patients did not differ from controls in COVID-19 infection and vaccine status, and behavioral avoidance of COVID-19. No demographic and clinical factor significantly affected the COVID-19 infection status. Patients scored higher than controls in the perception of COVID-19 as contagious (p = 0.038), cognitive avoidance of COVID-19 (p = 0.008), and positive attitudes toward the COVID-19 vaccine (p = 0.024). After adjustment of possible factors, a positive perception of the COVID-19 vaccine and a perception of COVID-19 as dangerous were the two factors significantly affecting behavioral avoidance of COVID-19 [R 2 = 0. 17, F(2) = 13.189, p < 0.0001]. Conclusion: Infection and vaccine status of COVID-19 in patients did not significantly differ from controls. No demographic and clinical factor significantly affected the COVID-19 infection status. Approximately four-fifths of the patients were fully vaccinated as recommended by national and global health organizations. This has increased the knowledge base showing that the COVID-19 vaccine is acceptable and receiving the vaccine is endorsed by ADHD patients. Attention deficit and hyperactivity disorder itself may provoke no kind of mental disturbance in sense of perception of the danger of this disease. Our findings have increased the knowledge base showing that the COVID-19 vaccine is acceptable and the actual practice of receiving the vaccine is endorsed in this population. Our message for practice would be to take into account not only the core symptoms and the comorbidities of the disorder but also the perception of the disease while exploring its link with COVID-19.Publication Metadata only Problematic Patient(2021-06-01T00:00:00Z) KIRPINAR, İSMET; Ayhan, M. Suhan; GÜNEREN, Ethem; KIRPINAR, İSMET; GÜNEREN, ETHEMThe group of patients defined as -problematic patient- in aesthetic plastic surgical practice has distinctive features. The -problematic patient- is the patient who blocks the establishment of a therapeutic relationship with him/her. In other words, the patient who does not adapt to the patient role that the health-care professional expects, has different values, beliefs, or personal characteristics than he/she expects to see, and sometimes causes the professional to even suspect himself/herself. They are not good candidates for esthetic surgery, and they should definitely not be operated, so to speak, these patients should be removed from the game by removing a red card, and somehow be disqualified from the process.Publication Metadata only Predictors of long-term anxiety and depression in discharged COVID-19 patients: A follow-up study(2022-08-01T00:00:00Z) Boyraz, Rabia Kevser; Şahan, Ebru; Boylu, Muhammed Emin; Kırpınar, İsmet; BOYLU, MUHAMMED EMİN; KIRPINAR, İSMETPublication Metadata only The Effects of Transcranial Focused Ultrasound Stimulation of Nucleus Accumbens on Neuronal Gene Expression and Brain Tissue in High Alcohol-Preferring Rats(2022-11-01) Deveci E.; Akbaş F.; Ergun A. Ş.; Kurtulmuş A.; Koçak A. B.; Boyraz R. K.; Tok O. E.; Aydın M. Ş.; Kılıç Ö.; Bozkurt A.; et al.; AKBAŞ, FAHRİ; KILIÇ, ÖZGE; EŞREFOĞLU, MUKADDES; KOÇYİĞİT, ABDÜRRAHİM; KIRPINAR, İSMETWe investigated the effect of low-intensity focused ultrasound (LIFU) on gene expression related to alcohol dependence and histological effects on brain tissue. We also aimed at determining the miRNA-mRNA relationship and their pathways in alcohol dependence-induced expression changes after focused ultrasound therapy. We designed a case-control study for 100 days of observation to investigate differences in gene expression in the short-term stimulation group (STS) and long-term stimulation group (LTS) compared with the control sham group (SG). The study was performed in our Experimental Research Laboratory. 24 male high alcohol-preferring rats 63 to 79 days old, weighing 270 to 300 g, were included in the experiment. LTS received 50-day LIFU and STS received 10-day LIFU and 40-day sham stimulation, while the SG received 50-day sham stimulation. In miRNA expression analysis, it was found that LIFU caused gene expression differences in NAc. Significant differences were found between the groups for gene expression. Compared to the SG, the expression of 454 genes in the NAc region was changed in the STS while the expression of 382 genes was changed in the LTS. In the LTS, the expression of 32 genes was changed in total compared to STS. Our data suggest that LIFU targeted on NAc may assist in the treatment of alcohol dependence, especially in the long term possibly through altering gene expression. Our immunohistochemical studies verified that LIFU does not cause any tissue damage. These findings may lead to new studies in investigating the efficacy of LIFU for the treatment of alcohol dependence and also for other psychiatric disorders.Publication Open Access COVID-19 Pandemic: Stress and Psychiatric Disorders(2021-02-01T00:00:00Z) KIRPINAR, İSMET; KIRPINAR, İSMETThe epidemic, which first started as viral pneumonia in Wuhan, China at the end of 2019 and is now known as Coronavirus disease-19 (COVID-19). rapidly spread to almost every part of the world and named a pandemic in March 2020. It is well known that psychiatric symptoms and syndromes, especially posttraumatic stress disorder, major depression, anxiety, and sleep disorders reach high prevalence values in natural or man-made disasters, Especially in infectious disease epidemics where mortality rates are high, patients, those who arc quarantined, and the whole society experience very intense mental stress and trauma. It is not easy to avoid psychological distress after facing highly fatal illnesses such as Ebola, severe acute respiratory syndrome (SARS), or COVID-19. When pandemics turn into a rapid and global disaster, the prevalence values of mental problems reach even higher levels. Combating mental disorders not only provides psychological well-being but also affects the course of the epidemic, as these disorders can delay efforts to fight epidemics. Mental health complaints increase in healthcare workers as a result of the stress and trauma of working during the epidemic. Studies report that during the SARS epidemic, approximately one-fifth of healthcare workers experienced 'significant mental disorders'. Medical professionals who develop mental disorders will be less productive, which will weaken the fight against the epidemic. Therefore, it is very important to support healthcare professionals. Since the COVID-19 outbreak is a relatively recent disaster, epidemiological study results have not yet been published sufficiently. However, the results of serious epidemics caused by viruses such as SARS and Ebola have previously been published. In this review, information about the psychiatric morbidity expected after COVID-19 is reviewed in the light of the results of studies conducted mainly in previous virus epidemics.Publication Metadata only Klinik uygulamada bilişsel Davranışçı Terapi-2(Nobel Yayın Dağıtım, 2022-10-01) Ak M.; Kırpınar İ.; Atmaca M.; KIRPINAR, İSMETPublication Open Access Can we predict who will be more anxious and depressed in the COVID-19 ward?(2021-01-01T00:00:00Z) Sahan, Ebru; Unal, Shafiga Mursalova; KIRPINAR, İSMET; ŞAHAN, EBRU; KIRPINAR, İSMETObjective: Hospitalized patients with COVID-19 are at high risk for anxiety and depression, but most studies about mental health during the pandemic included the general public, healthcare workers, and students. We aimed to explore the anxiety and depression levels, prevalence and predictors in patients hospitalized with COVID-19. Methods: In this cross-sectional, exploratory study, sociodemographic and clinical features of 281 patients with confirmed COVID-19 were explored. Patients underwent a comprehensive psychiatric assessment and the Hospital Anxiety and Depression Scale (HADS) was administered through a telephonic interview. Results: The mean age of the participants was 55.0 ± 14.9 years. One hundred forty-three (50.9%) patients were male, and 138 (49.1%) were female. Ninety-eight (34.9%) patients had significant levels of anxiety and 118 (42.0%) had significant levels of depression. Female gender, staying alone in a hospital room, early days of hospital stay, and any lifetime psychiatric disorder was associated with symptoms of anxiety. Being over 50 years of age, staying alone in a hospital room, and NSAID use before the week of hospital admission were associated with symptoms of depression. Anxiety and depression levels were lower when family members who tested positive for COVID-19 stayed in the same hospital room during treatment. Conclusion: Women, patients >50 years, patients who used NSAIDs before hospital admission, and those with lifetime psychiatric disorders may be at risk for anxiety and depressive symptoms in the COVID-19 ward. Allowing family members with COVID-19 to stay in the same hospital room may be associated with lower anxiety and depression levels.Publication Open Access A Treatment-Response Comparison Study of Resting-State Functional Magnetic Resonance Imaging Between Standard Treatment of SSRI and Standard Treatment of SSRI Plus Non-dominant Hand-Writing Task in Patients With Major Depressive Disorder(2021-09-01T00:00:00Z) BOYRAZ, Rabia Kevser; KIRPINAR, İSMET; YILMAZ, Onur; Ozyurt, Onur; KILIÇARSLAN, TEZER; ARALAŞMAK, Ayşe; BOYRAZ, RABIA KEVSER; KIRPINAR, İSMET; YILMAZ, ONUR; KILIÇARSLAN, TEZER; ARALAŞMAK, AYŞEBackground: Researches have recently shifted from functional/structural imaging studies to functional connectivity (FC) studies in major depressive disorder (MDD). We aimed to compare treatment response of two treatment groups before and after treatment, in terms of both with psychiatric evaluation scales and resting-state functional connectivity (RSFC) changes in order to objectively demonstrate the possible contribution of the non-dominant hand-writing exercise (NHE) effect on depression treatment.Publication Metadata only Psychosocial Adjustment of Healthcare Professionals During the COVID-19 Pandemic: Resident Doctors, Nurses, and Caregivers Need Extra Attention(2021-12-01) Karacan F. A.; Yilmaz S.; KIRPINAR İ.; KIRPINAR, İSMETObjective: This study aimed to examine the psychosocial adjustment and its association with occupation, hospital unit, social support, and Coronavirus disease-2019 (COVID-19) attitude in the healthcare professionals during the COVID-19 pandemic.Publication Open Access The first male case with fluoxetine induced hair loss and review of the literature(2021-01-01T00:00:00Z) Karacan, FATMA; Tangilntiz, A.; KIRPINAR, İSMET; AKYÜZ KARACAN, FATMA; TANGİLNTİZ, AİSE; KIRPINAR, İSMETObjective: Fluoxetine is the drug of choice in the treatment of depression. It is widely preferred due to fewer side effects and greater tolerability. Hair loss is a frequent adverse effect that may occur by psychotropic drug use and that can remit by its cessation. Patients and methods: We present the diagnosis and treatment of a 26-year-old male patient. He was diagnosed with depression without psychotic features according to the DSM-V criteria and was administered fluoxetine in a dose of 20 mg/day. Results: Six weeks after the initiation of the fluoxetine treatment, the patient reported hair loss in the frontal area of the skull. These complaints regressed after cessation of drug. Conclusions: Hair loss appears to be a rare side effect of fluoxetine-based treatment. Dermatologists and psychiatrists must be informed about this adverse side effect. There might be differences in the risk of hair loss between the various SSRIs and the risk might be higher in female than in male. This male patient was the first case as far as we know in the literature. It should be kept in mind that hair loss may be observed in patients treated with fluoxetine and should be questioned in both male and female.